Probiotic Psoriasis Meta-analysis: What the Evidence Says

Quick Answer

Probiotic Psoriasis Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The global prevalence of autoimmune diseases has been estimated at around 5-10% of the population, with some evidence indicating a rising trend, especially in industrialized nations. [Chiou Yuan-Yow (2026); evidence level 1]
• The cost associated with autoimmune diseases includes direct expenses such as medications, hospitalizations, and physician visits, and indirect costs like loss of productivity and reduced work capacity. [Chiou Yuan-Yow (2026); evidence level 1]
• Although the overall trends were declining, the burden among those aged 30-39 has increased, which potentially reduces the performance and economic contribution of this productive age group. [Ayuningtyas Maulidah (2026); evidence level 3]
• The need to conduct an umbrella review to identify, evaluate and synthesize the evidence is warranted, as there are numerous systematic reviews that assess the probiotics and psoriasis symptom relief. [Ayuningtyas Maulidah (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For probiotic psoriasis meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Chiou Yuan-Yow (2026). Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. DOI: 10.3390/nu18071107. PMCID: PMC13074674. PMID: 41978157. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13074674/
• Ayuningtyas Maulidah (2026). The Effectiveness of Probiotics in Psoriasis: An Umbrella Review. DOI: 10.1155/jnme/1120062. PMCID: PMC13089384. PMID: 42005309. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13089384/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.